1. Executive Summary
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Influenza Medication Market
4. Market Overview
4.1. Market Segmentation
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Influenza Medication Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. COVID-19 Pandemic Impact on Industry
6. Influenza Medication Market Analysis and Forecast, by Product Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product Type, 2017–2031
6.3.1. Zanamivir
6.3.2. Oseltamivir
6.3.3. Peramivir
6.3.4. Amantadine
6.3.5. Rimantadine
6.3.6. Inosine
6.3.7. Others (Laninamivir Octanoate, etc.)
6.4. Market Attractiveness, by Product Type
7. Global Influenza Medication Market Analysis and Forecast, by Distribution Channel
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Distribution Channel, 2023–2031
7.3.1. Hospitals
7.3.2. Clinics
7.3.3. Pharmacies
7.3.4. Others
7.4. Market Attractiveness, by Distribution Channel
8. Global Influenza Medication Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2017–2031
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region
9. North America Influenza Medication Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Product Type, 2017–2031
9.2.1. Zanamivir
9.2.2. Oseltamivir
9.2.3. Peramivir
9.2.4. Amantadine
9.2.5. Rimantadine
9.2.6. Inosine
9.2.7. Others (Laninamivir Octanoate, etc.)
9.3. Market Value Forecast, by Distribution Channel, 2017–2031
9.3.1. Hospitals
9.3.2. Clinics
9.3.3. Pharmacies
9.3.4. Others
9.4. Market Value Forecast, by Country, 2017–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Product Type
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Influenza Medication Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Product Type, 2017–2031
10.2.1. Zanamivir
10.2.2. Oseltamivir
10.2.3. Peramivir
10.2.4. Amantadine
10.2.5. Rimantadine
10.2.6. Inosine
10.2.7. Others (Laninamivir Octanoate, etc.)
10.3. Market Value Forecast, by Distribution Channel, 2017–2031
10.3.1. Hospitals
10.3.2. Clinics
10.3.3. Pharmacies
10.3.4. Others
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Product Type
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Influenza Medication Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product Type, 2017–2031
11.2.1. Zanamivir
11.2.2. Oseltamivir
11.2.3. Peramivir
11.2.4. Amantadine
11.2.5. Rimantadine
11.2.6. Inosine
11.2.7. Others (Laninamivir Octanoate, etc.)
11.3. Market Value Forecast, by Distribution Channel, 2017–2031
11.3.1. Hospitals
11.3.2. Clinics
11.3.3. Pharmacies
11.3.4. Others
11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Product Type
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region
12. Latin America Influenza Medication Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product Type, 2017–2031
12.2.1. Zanamivir
12.2.2. Oseltamivir
12.2.3. Peramivir
12.2.4. Amantadine
12.2.5. Rimantadine
12.2.6. Inosine
12.2.7. Others (Laninamivir Octanoate, etc.)
12.3. Market Value Forecast, by Distribution Channel, 2017–2031
12.3.1. Hospitals
12.3.2. Clinics
12.3.3. Pharmacies
12.3.4. Others
12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Product Type
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Influenza Medication Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product Type, 2017–2031
13.2.1. Zanamivir
13.2.2. Oseltamivir
13.2.3. Peramivir
13.2.4. Amantadine
13.2.5. Rimantadine
13.2.6. Inosine
13.2.7. Others (Laninamivir Octanoate, etc.)
13.3. Market Value Forecast, by Distribution Channel, 2017–2031
13.3.1. Hospitals
13.3.2. Clinics
13.3.3. Pharmacies
13.3.4. Others
13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Product Type
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. F. Hoffmann-La Roche Ltd.,
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. Financial Overview
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Teva Pharmaceutical Industries Ltd.
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. Financial Overview
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. Sandoz International GmbH
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. Financial Overview
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. Sun Pharmaceutical Industries Ltd.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. Financial Overview
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Mylan, Inc.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. Financial Overview
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. GlaxoSmithKline plc
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. Financial Overview
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. Daiichi Sankyo Company
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. Financial Overview
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. Natco Pharma
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. Financial Overview
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
